1. Sulphadoxine/pyrimethamine: an appropriate first-line alternative for the treatment of uncomplicated falciparum malaria in Ghanaian children under 5 years of age
- Author
-
J.P. Verhave, B.J.J.W. Schouwenberg, G.J.A. Driessen, S. van Kerkhoven, and G. Bonsu
- Subjects
Male ,medicine.medical_specialty ,Sulfadoxine ,medicine.medical_treatment ,Population ,Drug Resistance ,gastheer-parasiet interactie [Malaria] ,parasite-host interaction [Malaria] ,Drug resistance ,Ghana ,law.invention ,Antimalarials ,Randomized controlled trial ,law ,Chloroquine ,Internal medicine ,Outpatients ,medicine ,Humans ,Treatment Failure ,Malaria, Falciparum ,education ,education.field_of_study ,business.industry ,Public Health, Environmental and Occupational Health ,Infant ,medicine.disease ,Drug Combinations ,Pyrimethamine ,Treatment Outcome ,Infectious Diseases ,Clinical research ,Child, Preschool ,Immunology ,Female ,Parasitology ,business ,Malaria ,Follow-Up Studies ,medicine.drug - Abstract
Contains fulltext : 185489.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To assess whether chloroquine (CQ) still is an appropriate first-line drug for the treatment of uncomplicated falciparum malaria in Ghana and whether sulphadoxine/pyrimethamine (SP) could be a good alternative. METHOD: The parasitological, clinical and haematological responses to CQ and SP were studied in children < 5 years of age according to a modified WHO 28-day in vivo protocol. A total of 142 children attending the outpatients department meeting the inclusion criteria were randomly assigned to the CQ (n=72) or SP (n=70) group. RESULTS: In the CQ group, 15 children (20.8%) exhibited early clinical failure (within 3 days) compared with only 1 (1.4%) in the SP group (P < 0.01). The clinical failure rate before day 14 (early treatment failure plus late treatment failure before day 14) also showed a marked advantage in favour of the SP group (1.4 against 29.2%). The median time to clinical failure was 11.5 days in the CQ group and 26 days in the SP group (P < 0.01). Of the 72 children treated with CQ, 9 (12.5%) had RIII resistance and 19 (26.4%) had RII resistance. A total of 36 (50.0%) were sensitive to CQ. From the 70 children treated with SP, none had RIII or RII resistance. There was no difference in haematological response between the two treatment groups. CONCLUSION: Although there is little concordance on when to change treatment policy, the high resistance to CQ in this study supports the change to another first-line drug for children under 5 years of age. SP seems to be a good alternative, although a high RII and RIII resistance against this drug has already been reported in the coastal zones of Ghana.
- Published
- 2002
- Full Text
- View/download PDF